

Attachment 11: PLCO Manuscripts, Books & Book Chapters

1. Abnet CC, Chen Y, Chow W-H, Gao Y-T, Helzlsouer KJ, Le Marchand L, McCullough ML, Shikany JM, Virtamo J, Weinstein SJ, Xiang Y-B, Yu K, Zheng W, Albanes D, Arslan AA, Campbell DS, Campbell PT, Hayes RB, Horst RH, Kolonel LN, Nomura AMY, Purdue MP, Snyder K, and Shu X-O (2010). Circulating 25-Hydroxyvitamin D and Risk of Esophageal and Gastric Cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. *Am J Epidemiol*, 172 (1), 94-106.
2. Ahmed S, Thomas G, Ghousaini M, Healey CS, Humphreys MK, Platte R, Morrison J, Maraniam M, Pooley KA, Luben R, Eccles D, Evans DG, Fletcher O, Johnson N, Silva IdS, Peto J, Stratton MR, Rahman N, Jacobs K, Prentice R, Anderson GL, Rajkovic A, Curb JD, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Diver WR, Bojessen S, Nordestgaard BG, Flyger H, Dork T, Schurmann P, Hillemanns P, Karstens JH, Bogdanova NV, Antonekova NN, Zalutsky IV, Bermisheva M, Fedorova S, Khusnutdinova E, SEARCH, Kang D, Yoo KY, Noh DY, Ahn SH, Devilee P, vanAsperen CJ, Tollenaar RAEM, Seynaeve C, Garcia-Closas M, Lissowska J, Brinton L, Peplonska B, Nevanlinna H, Heikkinen T, Aittomaki K, Blomqvist C, Hopper JL, Southey MC, Smith L, Spurdle AB, Schmidt MK, Broeks A, vanHien RR, Cornelissen S., Burwinkel B, Bartram CR, Meindle A, Brauch H, Justenhoven C, Hamann U, the GENICA Consortium, Chang-Claude J, Australian Ovarian Cancer Study Group, Hein R, Want-Gohrke S, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Kataja V, Olson JE, Wang X, Fredericksen Z, Giles GG, Severi G, Baglietto L, English DR, Hankinson SE, Cox DG, Kraft P, Vatten LJ, Hveem K, Kumle M, Sigurdson A, Doody M, Bhatti P, Alexander BH, Hooning MJ, van der Ouweland AMW, Oldenburg RA, Schutte M, Hall P, Czene K, Liu J, Li Y, Cox A, Elliott G, Brock I, Reed MWR, Shen CY, Yu JC, Hsu GC, Chen ST, Anton-Culver H, Ziogas A, Andrulis IL, Knight JA, kConFab, Australian Ovarian Cancer Study Group, Beesley J, Goode EL, Couch F, Chenevix-Trench G, Hoover RN, Ponder BAJ, Hunter DJ, Pharoah PDP, Dunning AM, Chanock SJ, Easton DF (2009). Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nature Genetics*, 41 (5), 585-590.
3. Ahn J, Albanes D, Peters U, Schatzkin A, Lim U, Freedman M, Chatterjee N, Andriole GL, Leitzmann MF, Hayes RB; Prostate, Lung, Colorectal and Ovarian Trial Project Team (2007). Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. *Cancer Epidemiology, Biomarkers & Prevention*, 16 (12), 2623-2630.
4. Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, Freedman ND, Abnet CC, Huang WY, Kibel AS, Crawford ED, Weinstein SJ, Chanock SJ, Schatzkin A, Hayes RB for the Prostate, Lung, Colorectal and Ovarian (PLCO) Trial Project Team (2009). Vitamin D-related genes, serum vitamin D concentrations, and prostate cancer risk. *Carcinogenesis*, 30 (5), 769-776.
5. Ahn J, Berndt SI, Wacholder S, Kraft P, Kibel AS, Yeager M, Albanes D, Giovannucci E, Willett WC, Virtamo J, Thun MJ, Feigelson HS, Cancel-Tassin G, Cussenot O, Thomas G, Hunter DJ, Fraumeni JF, Hoover R, Chanock SJ, Hayes RB (2008). Variation in KLK Genes, Prostate Specific Antigen, and Risk of Prostate Cancer. *Nature Genetics*, 40 (9), 1032-1034.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

6. Ahn J, Moore SC, Albanes D, Huang WY, Leitzmann MF, Hayes RB (2009). Height and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *British Journal of Cancer*, 101, 522-525.
7. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB for the Prostate, Lung, Colorectal and Ovarian (PLCO) Trial Project Team (2008). Serum Vitamin D concentration and prostate cancer risk: A nested case-control study. *JNCI*, 100 (11), 796-804.
8. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, Jacobs EJ, Ascherio A, Helzlsouer K, Jacobs KB, Li Q, Weinstein SJ, Purdue M, Virtamo J, Horst R, Wheeler W, Chanock S, Hunter DJ, Hayes RB, Kraft P, and Albanes D (2010). Genome-wide association study of circulating vitamin D levels. *Hum Mol Genet*, 19 (13), 2739-2745.
9. Alexander FE, Andriole GL, Aus G, Auvinen A, Beensterboer P, Blijenberg BG, Bonardi R, Buys S, Canda (1999). (The International Prostate Screening Trial Evaluation Group) Review: rationale for randomised trials of prostate cancer screening. *The International Journal of Cancer*, 35 (2), 262-271.
10. Ali IU, Luke BT, Dean M, Greenwald P (2005). Allelic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. *British Journal of Cancer*, 93, 953-959.
11. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD for the PLCO Project Team (2009). Mortality results from a randomized prostate-cancer screening trial. *New England Journal of Medicine*, 360 (13), 1310-1319.
12. Andriole GL, Levin DL, Crawford D, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK (2005). Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. *Journal of the National Cancer Institute (JNCI)*, 97 (6), 433-438.
13. Andriole GL, Pinsky PF, Levin DL, Gelmann EP, Crawford ED, Reding DJ, Prorok PC, Gohagan JK (2004). The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: biopsy rates and cancer characteristics of initial (T0) screen. *Journal of Urology*, 171 (4 Suppl), 473.
14. Andriole GL, Reding D, Hayes RB, Prorok PC, Gohagan JK (2004). The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: status and promise. *Urologic Oncology: Seminars and Original Investigations*, 22 (4), 358-361.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

15. Arslan AA, Helzlsouer KJ, Kooperberg C, Shu X-O, Stepowski E, Bueno-de-Mesquita HB, Fuchs CS, Gross MD, Jacobs EJ, LaCroix AZ, Petersen GM, Stolzenberg-Solomon RZ, Zheng W, Albanes D, Amundadottir L, Bamlet WR, Barricarte A, Bingham SA, Boeing H, Boutron-Ruault M-C, Buring JE, Chanock SJ, Clipp S, Gaziano JM, Giovannucci EL, Hankinson SE, Hartge P, Hoover RN, Hunter DJ, Hutchinson A, Jacobs KB, Kraft P, Lynch SM, Manjer J, Manson JE, McTiernan A, McWilliams RR, Mendelsohn JB, Michaud DS, Palli D, Rohan TE, Slimani N, Thomas G, Tjonneland A, Tobias GS, Trichopoulos D, Virtamo J, Wolpin BM, Yu K, Zeleuiuch-Jacquotte A, Patel AV (2010). Anthropometric measures, body mass index, and pancreatic cancer. *Archives of Internal Medicine*, 170 (9), 791-780.
16. Auvinen A, Rietbergen JBW, Denis LJ, Schroder FH, Porok PC (1996). Prospective evaluation plan for randomised trials of prostate cancer screening. *Journal of Medical Screening*, 3, 97-104.
17. Azzato EM, Morton LM, Bergen AW, Wang SS, Chatterjee N, Kvale P, Yeager M, Hayes RB Chanock SJ & Caporaso NE (2009). SLC6A3 and body mass index in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *BMC Med Genet*, 10 (1), 9.
18. Baker SG, Kramer BS (2008). Estimating the cumulative risk of a false-positive under a regimen involving various types of cancer screening tests. *Journal of Medical Screening*, 15 (1), 18-22.
19. Barry MJ (2009). Screening for Prostate Cancer - The controversy that refuses to die. *New England Journal of Medicine*, 360 (13), 1351-1354.
20. Berndt SI, Chatterjee N, Huang WY, Chanock SJ, Welch R, Crawford ED, Hayes RB (2007). Variant in sex hormone-binding globulin gene and risk of prostate cancer. *Cancer Epidemiology Biomarkers Prevention*, 16 (1), 165-168.
21. Berndt SI, Huang WY, Chatterjee N, Yeager M, Welch R, Chanock SJ, Weissfeld JL, Schoen RE, Hayes RB (2007). Transforming growth factor beta 1 (TGFB1) gene polymorphisms and risk of advanced colorectal adenoma. *Carcinogenesis*, 28 (9), 1965-1970.
22. Berndt SI, Huang WY, Fallin MD, Helzlsouer KJ, Platz EA, Weissfeld JL, Church TR, Welch R, Chanock SJ, Hayes RB (2007). Genetic variation in base excision repair genes and the prevalence of advanced colorectal adenoma. *Cancer Research*, 67 (3), 1395-1404.
23. Berndt SI, Huang WY, Yeager M, Weissfeld JL, Chanock SJ, Hayes RB (2009). Genetic variants in the frizzled-related protein (FRZB) and the risk of colorectal neoplasia. *Cancer Causes Control*, 20 (4), 487-490.
24. Berndt SI, Potter JD, Hazra A, Yeager M, Thomas M, Makar KW, Welch R, Cross AJ, Huang WY, Schoen RE, Giovannucci E, Chan AT, Chanock SJ, Peters U, Hunter DJ, Hayes

Attachment 11: PLCO Manuscripts, Books & Book Chapters

- RB (2008). Pooled analysis of genetic variation at chromosome 8q24 and colorectal neoplasia risk. *Human Molecular Genetics*, 17 (17), 2665-2672.
25. Brock K, Huang W-Y, Fraser DR, Ke L, Tseng M, Stolzenberg-Solomon R, Peters U, Ahn J, Purdue M, Mason RS, McCarty C, Ziegler R, Graubard B (2010). Low vitamin D status is associated with physical inactivity, obesity and low vitamin D intake in a large US sample of healthy middle-aged men and women. *Journal of Steroid Biochemistry and Molecular Biology*, 121, 462-466.
 26. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley T, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK, for the PLCO Project Team (2005). Ovarian cancer screening in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screen of a randomized trial. *American Journal of Obstetrics and Gynecology*, 193, 1630-9.
 27. Canzian F, Cox DG, Setiawan VW, Stram DO, Ziegler RG, Dossus L, Beckmann L, Blanché H, Barricarte A, Berg CD, Bingham S, Buring J, Buys SS, Calle EE, Chanock SJ, Clavel-Chapelon F, DeLancey JO, Diver WR, Dorransoro M, Haiman CA, Hallmans G, Hankinson SE, Hunter DJ, Hüsing A, Isaacs C, Khaw KT, Kolonel LN, Kraft P, Le Marchand L, Lund E, Overvad K, Panico S, Peeters PH, Pollak M, Thun MJ, Tjønneland A, Trichopoulos D, Tumino R, Yeager M, Hoover RN, Riboli E, Thomas G, Henderson BE, Kaaks R, Feigelson HS (2010). Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. *Human Molecular Genetics*, 19 (19), 3872-3884.
 28. Caporaso N, Gu F, Chatterjee N, Sheng-Chih J, Yu K, Yeager M, Chen C, Jacobs K, Wheeler W, Landi MT, Ziegler R, Hunter DJ, Chanock S, Hankinson S, , Kraft P, Bergen AW (2009). Genome-wide and candidate gene association study of cigarette smoking behaviors. *PLoS One*, 4 (2), e4653.
 29. Chang SC, Ziegler RG, Dunn B, Stolzenberg-Solomon R, Lacey JV, Huang WY, Schatzkin A, Reding D, Hoover RN, Hartge P, Leitzmann FF (2006). Association of energy intake and energy balance with postmenopausal breast cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Cancer Epidemiology Biomarkers Prevention*, 15 (2), 334-341.
 30. Chatterjee N & Chen YH (2007). Maximum-likelihood inference on a novel regression model for genetic epidemiologic studies with two-phase sampling. *Journal of the Royal Statistical Assoc., Series B*, 69 (2), 123-142.
 31. Chatterjee N, Kalaylioglu Z, Moslehi R, Peters U, Wacholder S (2006). Powerful multilocus tests of genetic association in the presence of gene-gene and gene-environment interactions. *The American Journal of Human Genetics*, 79, 1002-1016.
 32. Chen GK, Millikan RC, John EM, Ambrosone CB, Bernstein L, Zheng W, Hu JJ, Chanock SJ, Ziegler RG, Bandera EV, enderson BE, Haiman CA, and Stram DO (2010). The Potential

Attachment 11: PLCO Manuscripts, Books & Book Chapters

for Enhancing the Power of Genetic Association Studies in African Americans through the Reuse of Existing Genotype Data. *PLoS Genet*, 6 (9), e1001096.

33. Chen YC, Kraft P, Bretsky P, Ketkar S, Hunter DJ, Albanes D, Altshuler D, Andriole G, Berg CD, Boeing H, Burt N, Bueno-de-Mesquita B, Cann H, Canzian F, Chanock S, Dunning A, Feigelson HS, Freedman M, Gaziano JM, Giovannucci E, Sanchez MJ, Haiman CA, Hallmans G, Hayes RB, Henderson BE, Hirschhorn J, Kaaks R, Key TJ, Kolonel LN, LeMarchand L, Ma J, Overvad K, Palli D, Pharaoh P, Pike M, Riboli E, Rodriguez C, Setiawan VW, Stampfer M, Stram DO, Thomas G, Thun MJ, Travis RC, Virtamo J, Trichopoulos A, Wacholder S, Weinstein SJ. (2007). Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. *Cancer Epidemiol Biomarkers Prev*, 165 (10), 1973-1981.
34. Chen YH, Chatterjee N, Carroll RJ (2008). Retrospective analysis of haplotype-based case-control studies under a flexible model for gene-environment association. *Biostatistics*, 9 (1), 81-99.
35. Chu LW, Meyer TE, Li Q, Menashe I, Yu K, Rosenberg PS, Huang W-Y, Quraishi SM, Kaaks R, Weiss JM, Hayes RB, Chanock SJ, Hsing AW (2010). Association between genetic variants in the 8q24 cancer risk region and circulating levels of androgens and sex hormone-binding globulin. *Cancer Epidemiology, Biomarkers and Prevention*, 19 (7), 1848-1854.
36. Church TR, Anderson KE, Caporaso NE, Geisser MS, Le CT, Zhang Y, Benoit AR, Carmella SG, Hecht SS (2009). A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. *Cancer Epidemiology Biomarkers Prevention*, 18 (1), 260-266.
37. Crawford ED, Pinsky PF, Chia D, Kramer BS, Fagerstrom RM, Andriole G, Reding D, Gelmann EP, Levin DL, Gohagan JK (2006). Prostate specific antigen changes as related to the initial prostate specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Journal of Urology*, 175, 1286-1290.
38. Cross AJ, Peters U, Kirsh VA, Andriole GL, Reding D, Hayes RC, Sinha R (2005). A prospective study of meat and meat mutagens and prostate cancer risk. *Cancer Research*, 65 (24), 11779-11784.
39. Crosswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, Fouad MN, Gelmann EP, Lamerato L, Reding DJ, Schoen RE (2009). Cumulative incidence of false-positive results in repeated, multi-modality cancer screening. *Annals of Family Medicine*, 7 (3), 212-222.
40. Crosswell JM, Baker SG, Marcus PM, Clapp JD, Kramer BS (2010). Cumulative incidence of false-positive test results in lung cancer screening. *Annals of Internal Medicine*, 152 (8), 505-512.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

41. Danforth KN, Hayes RB, Rodriguez C, Yu K, Sakoda LC, Huang WY, Chen BE, Chen J, Andriole GL, Calle EE, Jacobs EJ, Chu LW, Figueroa JD, Yeager M, Platz EA, Michaud DS, Chanock SJ, Thun MJ, Hsing AW (2008). Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. *Carcinogenesis*, 29 (3), 568-572.
42. Danforth KN, Rodriguez C, Hayes RB, Sakoda LC, Huang W-Y, Yu K, Calle EE, Jacobs EJ, Chen BE, Andriole GL, Figueroa JD, Yeager M, Platz EA, Michaud DA, Chanock SJ, Thun MJ, Hsing AW (2008). TNF polymorphisms and prostate cancer risk. *Prostate*, 68 (4), 400-407.
43. Daugherty SE, Hayes RB, Yeager M, Andriole GL, Chatterjee N, Huang W-Y, Isaacs WB, Platz EA (2007). RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. *The Prostate*, 67 (8), 849-854.
44. Daugherty SE, Platz EA, Shugart YY, Fallin MD, Isaacs WB, Chatterjee N, Welch R, Huang W-Y, Hayes RB (2007). Variants in the Alpha-Methylacyl-CoA Racemase Gene and the Association with advanced distal colorectal adenoma. *Cancer Epidemiol Biomarkers Prev*, 16 (8), 1536-1542.
45. Daugherty SE, Shugart YY, Platz EA, Fallin MD, Isaacs WB, Pfeiffer RM, Welch R, Huang WY, Reding D, Hayes RB (2007). Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer. *Prostate*, 67 (14), 1487-1497.
46. DeKoning HJ, Auvinen A, Sanchez AB, Da Silva FC, Ciatto SD, L, Gohagan JK, Hakama M, Hugosson J, Krr (2002). Large-scale randomized prostate cancer screening trials: program performance in the european randomized screening for prostate cancer trial and the Prostate, Lung, Colorectal and Ovary Cancer Screening Trial. *Int. Journal of Cancer*, 97, 237-244.
47. Dixon LB, Subar AF, Peters U, Weissfeld JL, Bresalier RS, Risch A, Schatzkin A, Hayes RB (2007). Adherence to the USDA Food Guide, DASH Eating Plan, and Mediterranean dietary pattern reduces risk of colorectal adenoma. *Journal of Nutrition*, 137 (11), 2443-2450.
48. Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanock SJ, Clavel-Chapelon F, Feigelson HS, Ganziano JM, Giovannucci E, Gonzales C, Haiman CA, Hallmans G, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Hunter DJ, Khaw RT, Kolonel LN, Kraft P, Ma J, Le Marchand L, Lund E, Peeters PH, Stampfer M, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Riboli E, Virtamo J, Weinstein SJ, Yeager M, Ziegler RG, Cox DG. (2010). PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: Results from the Breast and Prostate Cancer Cohort Consortium (BPC3). *Carcinogenesis*, 31 (3), 455-461.
49. Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanock SJ, Clavel-Chapelon F, Feigelson HS, Ganziano JM, Giovannucci E, Gonzales C, Haiman CA, Hallmans G, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Hunter DJ, Khaw RT, Kolonel LN, Kraft P, Ma J, LeMarchand L, Lund E, Peeters PH, Stampfer M, Stram DO,

Attachment 11: PLCO Manuscripts, Books & Book Chapters

- Thomas G, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Riboli E, Virtamo J, Weinstein SJ, Yeager M, Ziegler RG, Cox DG (2009). PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: Results from the Breast and Prostate Cancer Cohort Consortium (BPC3). *Carcinogenesis*, epub ahead.
50. Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ (2010). Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Cancer Epidemiology, Biomarkers and Prevention*, 19 (9), 2298-2306.
51. Douglas JB, Silverman DT, Weinstein SJ, Graubard BI, Pollak MN, Tao Y, Jarmo V, Albanes D, Stolzenberg-Solomon RZ (2010). Serum C-reactive protein and risk of pancreatic cancer in two nested, case-control studies. *Cancer Epidemiology, Biomarkers & Prevention*, Epub ahead of print.
52. Endogenous Hormones and Breast Cancer Collaborative Group (2010). Insulin-like growth factors 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis for 17 prospective studies. *The Lancet Oncology*, 11 (6), 530-542.
53. Erichsen HC, Peters U, Eck P, Welch R, Schoen RE, Yeager M, Levine M, Hayes RB, Chanock S (2008). Genetic variation in sodium-dependent Vitamin C transporters SLC23A1 and SLC23A2 and risk of advanced colorectal adenoma. *Nutrition and Cancer*, 60 (5), 652-659.
54. Feigelson HS, Calle EE, Thun MJ, Diver R, Prentice R, Jackson R, Kooperberg C, Chlebowski R, Lissowska J, Peplonska B, Brinton LA, Sigurdson A, Doody M, Bhatti P, Alexander BH, Buring J, Lee IM, Vatten LJ, Hveem K, Kumle M, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF, Hoover RN, Chanock SJ, Hunter DJ (2009). A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). *Nat genet*, 41 (5), 579-584.
55. Ferrucci LM, Cross AJ, Graubard BI, Brinton LA, McCarty CA, Ziegler RG, Ma X, Mayne ST, Sinha R (2009). Intake of meat, meat mutagens and iron and the risk of breast cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *British Journal of Cancer*, epub ahead of print.
56. Ferrucci LM, Cross AJ, Gunter MJ, Ahn J, Mayne ST, Ma X, Chanock SJ, Yeager M, Graubard BI, Berndt SI, Huang WY, Hayes RB, Sinha R. (2010). 52. Ferrucci LM, Cross AJ, Gunter MJ, Ahn J, Mayne ST, Ma X, Chanock SJ, Yeager M, Graubard BI, Berndt SI, Huang WY, Hayes RB, Sinha R.. *World Rev Nutr Diet*, 101, 34-45.
57. Flood A, Peters U, Jenkins DJ, Chatterjee N, Subar AF, Church TR, Bresalier R, Weissfeld JL, Hayes RB, Schatzkin A (2006). Carbohydrate, glycemic index, and glycemic load and colorectal adenomas in the Prostate, Lung, Colorectal, and Ovarian Screening Study. *American Journal of Clinical Nutrition*, 84 (5), 1184-1192.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

58. Ford GM, Hegmann KT, White GL, Holmes EB (2005). Associations of body mass index with meniscal tears. *American Journal of Preventive Medicine*, 28 (4), 364-368.
59. Ford M.E., Havstad S.L., Flickinger L., Johnson C.C. (2003). Examining the effects of false positive lung cancer screening results on subsequent lung cancer screening adherence. *Cancer, Epidemiology, Biomarkers and Prevention*, 12 (1), 28-33.
60. Ford ME, Havstad MA, Tilley BC (2003). Recruiting older african american men to a cancer screening trial (The AAMEN Project). *The Gerontologist*, 43 (1), 27-35.
61. Ford ME, Havstad S, Stallings FL (1998). Recruiting black men to a clinical trial to evaluate prostate cancer screening. *Morbidity and Mortality Weekly Report*, 47, 694-696.
62. Ford ME, Havstad SL, Davis SD (2004). A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. *Society for Clinical Trials*, 1, 343-351.
63. Ford ME, Havstad SL, Demers R, Johnson CC (2005). Effects of false-positive prostate cancer screening results on subsequent prostate cancer screening behavior. *Cancer Epideimology Biomarkers & Prevention*, 14 (January), 190-194.
64. Ford ME, Havstad SL, Fields ME, Manigo B, McClary B, & Lamerato L. (2008). Effects of baseline comorbidities on cancer screening trial adherence among older African American men. *Cancer Epidemiol Biomarkers Prev*, 17 (5), 1234-1239.
65. Ford ME, Havstad SL, Tilley BC (2003). Recruiting older African American men to a cancer screening trial (The AAMEN Project). *The Gerontologist*, 43, 27-35.
66. Ford ME, Havstad SL, Tilley BC (2003). The Science of Inclusion: Recruiting and Retaining Racial and Ethnic Elders in Health Research. In In L Curry and J Jackson (Ed.), *Recruiting Older African American Men to a Cancer Screening Trial (the AAMEN Project)*. (pp. 26-34). Washington, DC: The Gerontological Society of America.
67. Ford ME, Randolph V, Hopkins-Johnson L, Eason SL, Havstad S, Jankowski M, Swanson GM, Johnson CC, Vernon SW (2004). Design of a case management approach to enhance cancer screening trial retention among older African American men. *Journal of Aging Health*, 16 ((5 Suppl)), 39S-57S.
68. Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA, Hollis BW, Graubard BI, Berg CD, Ziegler RG (2008). Serum levels of vitamin D metabolites and breast cancer risk in the Prostate, Lung Colorectal and Ovarian Cancer Screening Trial. *Cancer Epidemiology ,Biomarkers & Prev*, 17 (4), 889-894.
69. Gallicchio L, Helzlsouer KJ, Chow W-H, Freedman DM, Hankinson SE, Hartge P, Hartmuller V, Harvey C, Hayes RB, Horst RL, Koenig KL, Kolonel LN, Laden F, McCullough ML, Parisi D, Purdue MP, Shu X-O, Snyder K, Stolzenberg-Solomon RZ,

Attachment 11: PLCO Manuscripts, Books & Book Chapters

- TwoRoger SS, Varanasi A, Virtamo J, Wilkens LR, Xiang Y-B, Yu K, Zeleniuch-Jacquotte A, Zheng W, Abnet CC, Albanes D, Bertrand K, Weinstein SJ (2010). Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. *American Journal of Epidemiology*, 172 (1), 10-20.
70. Gallicchio L, Moore LE, Stevens VL, Ahn J, Albanes D, Hartmuller V, Setiawan VW, Helzlsouer K, Yang G, Xiang Y-B, Shu X-O, Snyder K, Weinstein SJ, Yu K, Zeleniuch-Jacquotte A, Zheng W, Cai Q, Campbell DS, Chen Y, Chow W-H, Horst RL, Kolonel LN, McCullough M, Purdue MP, Koenig K (2010). Circulating 25-hydroxyvitamin D and risk of kidney cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. *American Journal of Epidemiology*, 172 (1), 47-57.
71. Gelman EP, Chia D, Pinsky PF, Andriole GL, Crawford ED, Reding D, Hayes RB, Kramer BS, Woodrum DL, G (2001). Relationship of demographic and clinical factors to free and total PSA. *Urology*, 58 (4), 561-566.
72. Gohagan JK (1997). PLCO Screening Trial. *AUA News*, 11.
73. Gohagan JK, Kramer BS, & Greenwald P (1994). Screening for prostate cancer. *American Journal of Preventive Medicine*, 10 (4), 245-246.
74. Gohagan JK, Marcus PM, Fagerstrom RM et al (2003). Evidence Based Oncology. In Williams C (Ed.), *Screening for lung cancer*. (pp. 164-171). London, UK: BMJ Publishing Group.
75. Gohagan JK, Prorok PC, Hayes R, Kramer BS (2000). The Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer Screening Trial of the National Cancer Institute: history, organization, and status. *Controlled Clinical Trials*, 21 (6S), 251S-272S.
76. Gohagan JK, Prorok PC, Kramer BS, Cornett JE (1994). Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial of the National Cancer Institute. *Journal of Urology*, 152 (5), 1905-1909.
77. Gohagan JK, Prorok PC, Kramer BS, et al (1995). The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial of the National Cancer Institute. *Cancer Supplement*, 75 (7), 1869-1873.
78. Gohagan J, Prorok P, Kramer B, Cornett J (1995). Epithelial Cancer of the Ovary. In Lawton FG, Neijt JP, Swenerton KD (Ed.), *Screening for Ovarian Cancer: Epidemiological Aspects, Study Design, and Target Population*. (pp. 59-67). London, UK: BMJ Publishing Group.
79. Greenlee RT, Kessel B, Williams CR, Riley TL, Ragard LR, Hartge P, Buys SS, Partridge EE, Reding DJ (2010). Prevalence, incidence, and natural history of simple ovarian cysts among women >55 years old in a large cancer screening trial. *American Journal of Obstetrics and Gynecology*, epub ahead of print.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

80. Gren L, Broski K, Childs J, Cordes J, Engelhard D, Gahagan B, Gamito E, Gardner V, Geisser M, Higgins D, Jenkins V, Lamerato L, Lappe K, Lowery H, McGuire C, Miedzinski M, Ogden S, Tenorio S, Watt G, Wohlers B, Marcus P (2009). Recruitment methods employed in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Clinical Trials*, 6, 52-59.
81. Grubb RL, Black A, Church TR, Hickey T, Izmirlian G, Riley T, Prorok PC, Berg CD, Crawford ED, Andriole GL (2009). Effect of obesity at age 20 and 50 on development of prostate cancer in the PLCO Cancer Screening trial. *Journal of Urology*, 181 (4), 61-62.
82. Grubb RL, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, Riley TL, Mabile JE, Levin DL, Chia D, Kramer BS, Reding DJ, Church TR, Yokochi LA, Kvale PA, Weissfeld JL, Urban DA, Buys SS, Gelmann EP, Ragard LR, Crawford ED, Prorok PC, Gohagan JK, Berg CD, Andriole GL, for the PLCO Project Team (2008). Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Update on findings from the initial four rounds of screening in a randomized trial. *British Journal of Urology International*, 102, 1524-1530.
83. Grubb, RL, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabile JE, Riley TL, Ragard LR, Prorok PC, Berg CD, Crawford ED, Church TR, Andriole GL for the PLCO Project Team (2009). Serum PSA hemodilution among obese men undergoing screening in the PLCO Cancer Screening Trial. *Cancer Epidemiology, Biomarkers & Prevention*, 18 (3), 748.
84. Gunter MJ, Hayes RB, Chatterjee N, Yeager M, Welch R, Schoen RE, Yokochi L, Schatzkin A, Peters U (2007). Insulin resistance-related genes and advanced left-sided colorectal adenoma. *Cancer Epidemiol Biomarkers Prev*, 16 (4), 703-708.
85. Gupta AK, Pinsky P, Rall C, Mutch M, Dry S, Seligson D, Schoen RE (2009). Reliability and accuracy of endoscopic appearance in the identification of aberrant crypt foci. *Gastrointestinal Endoscopy*, 70 (2), 322-330.
86. Hartge P, Hayes R, Reding D, Sherman ME, Prorok P, Schiffman M, Buys S (2000). Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors. *Am. J Obstet Gynecol*, 83 (5), 1232-1237.
87. Hasson MA, Fagerstrom R, Kahane DC, Walsh JH, Myers MH, Caughman C, Wenzel B, Haralson JC, Flickinger LM, Turner LM (2000). Design and evolution of the data management systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Controlled Clinical Trials*, 21 (6S), 329S-348S.
88. Hayes RB, Reding D, Kopp W, Subar AF, Bhat N, Rothman N, Caporaso N, Ziegler R, Johnson CC, Weissfeld J, Hoover RN, Hartge P, Palace C, Gohagan JK (2000). Etiologic and early marker studies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Controlled Clinical Trials*, 21 (6S), 349S-355S.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

89. Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, Reding D, Gelmann EP, Rothman N, Pfeiffer RM, Hoover RN, Berg CD (2005). Methods for etiologic and early marker investigations in the PLCO trial. *Mutation Research*, 592, 147-154.
90. Hayes RB, Smith CO, Huang WY, Read Y, Kopp WC (2002). Whole blood cryopreservation in epidemiological studies. *Cancer Epidemiology Biomarkers Prevention*, 11, 1496-1498.
91. Helzlsouer KJ for the VDPP Steering Committee (2010). Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. *American Journal of Epidemiology*, 172 (1), 4-9.
92. Hocking WG, Oken MM, Winslow SD, Kvale PA, Prorok PC, Ragard LR, Commins J, Lynch DA, Andriole GL, Buys SS, Fouad MN, Fuhrman CR, Isaacs C, Yokochi LA, Riley TL, Pinsky PF, Gohagan JK, Berg CD for the PLCO Project Team (2010). Lung Cancer Screening in the Randomized Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *JNCI*, 102 (10), 722-731.
93. Hofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP (2010). Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Cancer Epidemiology, Biomarkers and Prevention*, 19 (4), 927-931.
94. Hou L, Chatterjee N, Huang WY, Baccarelli A, Yadavalli S, Yeager M, Bresalier RS, Chanock SJ, Caporaso NE, Ji BT, Weissfeld JL, Hayes RB (2005). CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use and risk for colorectal adenom. *Carcinogenesis*.
95. Huang WY, Berndt SI, Kang D, Chatterjee N, Chanock SJ, Yeager M, Welch R, Bresalier RS, Weissfeld JL, Hayes RB (2006). Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma: XPC polymorphisms modify smoking-related risk. *Cancer Epidemiology Biomarkers Prevention*, 15 (2), 306-311.
96. Huang WY, Chatterjee N, Chanock S, Dean M, Yeager M, Schoen RE, Hou LF, Berndt SI, Yadavalli S, Johnson CC, Hayes RB (2005). Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma. *Cancer Epidemiology, Biomarkers & Prevention*, 14 (1), 152-157.
97. Huang WY, Hayes R, Pfeiffer R, Viscidi R, Lee F, Wang YF, Reding D, Whitby D, Papp JR, Rabkin CS. (2008). Sexually transmissible infections and prostate cancer risk. *Cancer Epidemiol Biomarkers Prev*, 17 (9), 1274-2381.
98. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Callee EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover RN, Thomas G, Chanock SJ. (2007). A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. *Nature Genetics*, 39 (7), 870-874.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

99. Izmirlian G, Grubb RL, Black A, Prorok PC, Berg CD, Crawford ED, Andriole GL, Kibel AS (2009). Pre-biopsy prostate cancer nomograms based upon serial PSA screening data in the PLCO trial with verification bias correction. *Journal of Urology*, 181 (4), 609.
100. Ji BT, Weissfeld JL, Chow WH, Huang WY, Schoen RE, Hayes RB for the Prostate, Lung, Colorectal and Ovarian Trial Team (2006). Tobacco smoking and colorectal hyperplastic and adenomatous polyps. *Cancer Epidemiol Biomarkers Prev*, 15 (5), 897-901.
101. Johnson CC, Hayes RB, Schoen RE, Gunter MJ, Huang W-Y for the PLCO Trial Team (2010). Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *American Journal of Gastroenterology*, epub ahead of print.
102. Johnson CC, Kessel B, Riley TL, Ragard LR, Williams CR, Xu JL, Buys SS; for the PLCO Project Team (2008). The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. *Gynecol Oncol*, 110 (3), 383-389.
103. Johnson D (2006). The effects of an abnormal cancer screening test on health related quality of life. *International Journal of Cancer Research*, 2 (3), 277-289.
104. Kang D, Andriole GL, Van de Vooren RC, Crawford D, Chia D, Urban DA, Reding D, Huang WY, Hayes RB (2004). Lower Urinary Tract - Risk Behaviours and benign prostatic hyperplasia. *British Journal of Urology*, 93, 1241-1245.
105. Kang D, Lee KM, Park SK, Berndt SI, Peters U, Reding D, Chatterjee N, Welch R, Chanock S, Huang WY, Hayes RB (2007). Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. *Cancer Epidemiol Biomarkers Prev*, 16 (8), 1581-1586.
106. Kang D, Lee KM, Park SK, Berndt SI, Reding D, Chatterjee N, Welch R, Chanock S, Huang WY, Hayes RB (2007). Lack of association of transforming growth factor-beta1 polymorphisms and haplotypes with prostate cancer risk in the prostate, lung, colorectal, and ovarian trial. *Cancer Epidemiol Biomarkers Prev*, 16 (6), 1303-1305.
107. Kim, YI (2006). Does a high folate intake increase the risk of breast cancer?. *Nutr Rev*, 64 (10 PT1), 468-475.
108. Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, Albanes D, Andriole GL, Urban DA, Peters U (2006). Supplemental and dietary vitamin E, beta carotene, and vitamin C intakes and prostate cancer risk. *Journal of the National Cancer Institute (JNCI)*, 98 (4), 245-254.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

109. Kirsh VA, Mayne ST, Peters U, Chatterjee N, Leitzmann MF, Dixon LB, Urban DA, Crawford ED, Hayes RB (2006). A prospective study of lycopene and tomato product intake and risk of prostate cancer. *Cancer Epidemiology Biomarkers Prevention*, 15 (1), 92-98.
110. Kocarnik JD, Hutter CM, Slattery ML, Berndt SI, Hsu L, Duggan DJ, Muehling J, Caan BJ, Beresford SA, Rajkovic A, Sarto GE, Marshall JR, Hammad N, Wallace RB, Makar KW, Prentice RL, Potter JD, Hayes RB, Peters U (2010). Characterization of 9p24 risk locus and colorectal adenoma and cancer: gene-environment interaction and meta-analysis. *Cancer Epidemiol Biomarkers Prev.*, 19 (12), 3131-3139.
111. Koralek DO, Peters U, Andriole G, Reding D, Kirsh V, Subar A, Schatzkin A, Hayes R, Leitzmann MF (2006). A prospective study of dietary alpha-linolenic acid and the risk of prostate cancer (United States). *Cancer Causes Control*, 17, 783-791.
112. Koutros S, Berndt SI, Sinha R, Ma X, Chatterjee N, Alavanja MCR, Zheng T, Huang WY, Hayes RB, Cross AJ (2009). Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. *Cancer Research*, 69 (5), 1877-1884.
113. Koutros S, Schumacher FR, Ma J, Huang WY, Hayes RB, Berndt SI (2010). Pooled analysis of phosphatidylinositol3-kinase (PI3K) pathway variants and risk of prostate cancer. *Cancer Research*, epub ahead of print.
114. Kraft P, Pharoah P, Chanock SJ, Albanes D, Kolonel LN, Hayes RB, Altshuler D, Andriole G, Berg C, Boeing H, Burt NP, Bueno-de-Mesquita B, Calle EE, Cann H, Canzian F, Chen YC, Crawford DE, Dunning AM, Feigelson HS, Freedman ML, Gaziano JM, Giovannucci E, Gonzalez CA, Haiman CA, Hallmans G, Henderson BE, Hirschhorn JN, Hunter DJ, Kaaks R, Key T, Le Marchand L, Ma J, Overvad K, Palli D, Pike MC, Riboli E, Rodriguez C, Setiawan WV, Stampfer MJ, Stram DO, Thomas G, Thun MJ, Travis R, Trichopoulou A, Virtamo J, Wacholder S (2005). Genetic variation in the HSD17B1 gene and risk of prostate cancer. *PLoS Genetic*, 1 (5), e68.
115. Kramer BS, Gohagan J, Prorok PC (1994). NIH consensus 1994: Screening. *Gyn Oncol*, 55, S20-S21.
116. Kramer BS, Brown ML, Gohagan JK, Prorok PC, Potosky AL (1993). Prostate cancer screening: what we know and what we need to know. *Annals of Internal Medicine*, 119 (9), 914-923.
117. Kramer BS, Gohagan J, Prorok PC, Smart C (1993). A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian Cancers. *Cancer*, 71 (2), S589-593.
118. Kuznetsov IB, McDuffie M, Moslehi R (2009). A web-server for inferring the human N-acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype. *Bioinformatics*, 25 (9), 1185-1186.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

119. Lacey JV, Kreimer AR, Buys SS, Marcus PM, Chang SC, Leitzmann MF, Hoover RN, Prorok PC, Berg CD, Hartge P. and Prostate, Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial Team (2009). Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. *BMC Cancer*, 9 (1), 84.
120. Lafata JE, Simpkins J, Lamerato L, Poisson L, Divine G, Johnson CC (2004). The economic impact of false-positive cancer screens. *Cancer Epidemiology, Biomarkers & Prevention*, 13 (12), 2126-32.
121. Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose P, Bresalier R, Lamerato, LE, Crawford ED, Kvale P, Fouad M, Hickey T, Riley T, Weissfeld J, Schoen RE, Marcus PM, Prorok PC, Berg CD (2010). Race and colorectal cancer disparities: healthcare utilization versus different cancer susceptibilities. *Journal of the National Cancer Institute*, epub ahead.
122. Lamerato LE, Marcus PM, Jacobsen F, Johnson CC (2008). Recruitment in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: The first Phase of Recruitment at Henry Ford health system. *Cancer Epidemiology Biomarkers Prev*, 17 (4), 827-833.
123. Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P, Marti GE, Caporaso NE (2009). B-cell clones as early markers for chronic lymphocytic leukemia. *New England Journal of Medicine*, 360 (7), 659-667.
124. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, and Rajkumar SV (2009). Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. *Blood*, 113 (22), 5412-5417.
125. Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, Mirabello L, Jacobs K, Wheeler W, Yeager M, Bergen AW, Li O, Consonni D, Pesatori AC, Wacholder S, Thun M, Diver R, Oken M, Virtamo J, Albanes D, Wang Z, Burdette L, Doherty KF, Pugh EW, Laurie C, Brennan P, Hung R, Gaborieau V, McKay JD, Lathrop M, McLaughlin J, Wang Y, Tsao MS, Spitz MR, Wang Y, Krokan H, Vatten L, Skorpén F, Arnesen E, Benhamou S, Bouchard C, Metsapalu A, Vooder T, Nelis M, Vålk K, Field JK, Chen C, Goodman G, Sulem P, Thorleifsson G, Rafnar T, Eisen T, Sauter W, Rosenberger A, Bickeböller H, Risch A, Chang-Claude J, Wichmann HE, Stefansson K, Houlston R, Amos CI, Fraumeni, Jr. JF, Savage SA, Bertazzi PA, Tucker MA, Chanock S, and Caporaso NE. (2009). A Genome-wide Association Study of Lung Cancer Identifies a Region of Chromosome 5p15 Associated with Risk for Adenocarcinoma. *American Journal of Human Genetics*, 85 (5), 679-691.
126. Landren O, Kyle RA, Pfeiffer RM, Katzman JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV (2009). Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma: a prospective study. *Blood*, 113 (22), 5412-5417.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

127. Larkey LK, Ogden SL, Tenorio S, Ewell T (2008). Latino Recruitment to Cancer Prevention/Screening Trials in the Southwest: setting a research agenda. *Applied Nursing Research*, 21, 30-39.
128. Lee KM, Kang D, Park SK, Berndt SI, Reding D, Chatterjee N, Chanock S, Huang WY, Hayes RB (2009). Nitric oxide synthase gene polymorphisms and prostate cancer risk. *Carcinogenesis*, 30 (4), 621-625.
129. Leitzmann MF, Ahn J, Albanes D, Hsing AW, Schatzkin A, Chang SC, Huang WY, Weiss JM, Danforth KN, Grubb RL 3rd, Andriole GL,; for the Prostate, Lung, Colorectal and Ovarian (PLCO) Trial Project Team (2008). Diabetes mellitus and prostate cancer risk in the Prostate, Lung colorectal and Ovarian Cancer Screening Trial. *Cancer Causes Control*, 19 (10), 1267-1276.
130. Lettre G, Jackson AU, Gieger C, Schumacher FR, Berndt SI, Serena Sanna, Eyheramendy S, Voight BF, Butler JL, Guiducci C, Illig T, Hackett R, Heid IM, Jacobs KB, Lyssenko V, Uda M, The Diabetes Genetics Initiative, FUSION, KORA, The Prostate, Lung Colorectal and Ovarian Cancer Screening Trial, The Nurses' Health Study, SardiNIA, Boehnke M, Chanock SJ, Groop LC, Hu FB, Isomaa B, Peter , Hunter DJ, Hayes RB, Abecasis GR, Wichmann H-E, Mohlke KL, and Hirschhorn JN (2008). Identification of ten loci associated with height highlights new biological pathways in human growth. *Nat Genet*, 40 (5), 584-591.
131. Li H, Gail MH, Berndt S & Chatterjee N (2010). Using cases to strengthen inference on the association between single nucleotide polymorphisms and a secondary phenotype in Genome-Wide Association Studies. *Genetic Epidemiology*, 34 (5), 427-433.
132. Li Q, Wacholder S, Hunter DJ, Hoover RN, Chanock S, Thomas G, and Yu K (2009). Genetic Background Comparison Using Distance-based Regression, with Applications in Population Stratification Evaluation and Adjustment. *Genet Epidemiol*, 33 (5), 432-441.
133. Lingyi Lu, Jieli Sun, Sarah D. Isaacs, Kathleen E. Wiley, Shelly Smith, Kristen Pruett, Yi Zhu, Zheng Zhang, Fredrik Wiklund, Henrik Grönberg, Patrick C. Walsh, Bao-Li Chang, S. Lilly Zheng, William B. Isaacs, and Jianfeng Xu (2009). Fine mapping and family-based association analyses of prostate cancer risk variants at Xp11. *Cancer Epidemiol Biomarkers Prev*, 18 (7), 2132-2136.
134. Loos M, RJF, Lingren C, Li S, Wheeler E, Zhao JH, Prokopenko I, Attwood AP, Beckmann JS, Berndt SI, PLCO, Bennett A, Bingham SA, Smith GD, De S, Doney ASF, Elliott KS, Elliott P, Evans D, Farooqi S, Freathy RM, Ghorri J, Groves CJ, Gwilliam R, Hadley D, Hall A, Hattersley AT, Hebebrand J, Heid IM, KORA, Herrera B, Hunt S, Jarvelin M-R, Inouye M, Johnson T, Karpe F, Kenniry A, Khaw K-T, Luben R, Mangino M, McArdle W, McGinnis R, Munrow P, Morris AD, Ness AR, Nica A, Ong KK, O'Rahilly S, Owen K, Palmer CN, Papdakis K, Potter S, Pouta A, Qj L, Nurses Health Study, Randall JC, Rayner NW, Ring SM, Sandhu MS, Sims MA, Song K, Soranzo N, Speliotes EK, Diabetes Genetics Initiative, Teichmann SA, Timpson NJ, Uda M, The SardiNIA Study, Wallace C, Waterworth D, Weedon MN, The Wellcome Trust Case Control Consortium, Willer CJ,

Attachment 11: PLCO Manuscripts, Books & Book Chapters

- FUSION, Wraight V, Yuan X, Zeggini E, Hirschorn JN, Strachan DP, Ouwehand W, Caulfield M, Samani N, Ranyling TM, Vollenweider P, Waeber G, Mooser V, Deloukas P, McCarthy MI, Wareham NJ, Barroso I. (2008). Common variants near MC4R are associated with fat mass, weight and risk of obesity. *Nature Genetics*, 40 (6), 768-775.
135. Lu L, Sun J, Isaacs SD, Wiley KE, Smith S, Pruett K, Zhu Y, Zhang Z, Wiklund F, Grönberg H, Walsh PC, Chang B-L, Zheng SL, Isaacs WB, and Xu J (2009). Fine mapping and family-based association analyses of prostate cancer risk variants at Xp11. *Cancer Epidemiol Biomarkers Prev*, 18 (7), 2132-2136.
136. Lubahn J, Berndt SI, Jin CH, Klim A, Luly J, Wu WS, Isaacs S, Wiley K, Isaacs WB, Suarez BK, Hayes RB, Kibel AS (2010). Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. *Prostate*, 70 (6), 646-653.
137. Lubahn j, Berndt SI, Jin CH, Klim A, Luly J, Wu WS, Isaacs S, Wiley K, Isaacs WB, Suarez BK, Hayes RB, Kibel AS (2009). Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. *Prostate*, Epub ahead of print.
138. Lynch SM, Vrieling A, Lubin JH, Kraft P, Mendelsohn J, Hartge P, Canzian F, Bueno-de-Mesquita HB, Stolzenberg-Solomon RZ (2009). Cigarette smoking and pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort consortium (PANSCAN). *American Journal of Epidemiology*, 170 (4), 403-413.
139. McCullough ML, Weinstein SJ, Freedman DM, Helzlsouer K, Flanders WD, Koenig K, Kolonel L, Laden F, LeMarchand L, Purdue M, Snyder K, Stevens VL, Stolzenberg-Solomon R, Virtamo J, Yang G, Yu K, Zheng W, Albanes D, Ashby J, Bertrand K, Cai H, Chen Y, Gallicchio L, Giovannucci E, Jacobs, EJ, Hankinson SE, Hartge P, Hartmuller V, Harvey C, Hayes RB, Horst R, Shu X-O (2010). Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. *American Journal of Epidemiology*, 172 (11), 21-35.
140. McFarland EG, Brink JA (1999). Helical CT colongraphy (virtual colonoscopy): the challenge that exists between advancing technology and generalizability. *American Journal of Roentgenology*, 173, 549-559.
141. McFarland EG, Brink JA, Pilgram TK, Heiken JP, Balfe DM, Hirselj D, Weinstock L, Littenberg B (2001). Spiral CT colongraphy: reader agreement and diagnostic performance with two and three-dimensional image-display techniques. *Radiology*, 218 (2), 375-383.
142. McFarland EG, Brink JA, Pilgram TK, Mcdermott RA, Santillan CV, Brady PW, Heiken JP, Balfe DM, Weinstock LB, Thyssen EP, Littenberg B (2002). CT colongraphy: multiobserver diagnostic performance. *Radiology*, 225, 380-390.
143. McGlynn KA, Sakoda LC, Hu Y, Schoen RE, Bresalier RS, Yeager M, Chanock S, Hayes RB, Buetow KH (2005). Hemochromatosis gene mutations and distal adenomatous colorectal polyps. *Cancer Epidemiology, Biomarkers & Prevention*, 14 (1), 158-163.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

144. McGovern PM, Gross CR, Krueger RA, Engelhard DA, Cordes JE, Church TR (2004). False-positive cancer screens and health-related quality of life. *Cancer Nursing*, 27 (5), 347-352.
145. Meinhold CL, Dodd KW, Jiao L, Flood A, Shikany JM, Genkinger JM, Hayes RB, Stolzenberg-Solomon RZ. (2010). Available carbohydrates, glycemic load, and pancreatic cancer: Is there a link?. *American Journal of Epidemiology*, 171 (11), 1174-1182.
146. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY, Hayes RB (2006). Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. *Cancer Research*, 66 (8), 4525-4530.
147. Michaud DS, Vrieling A, Jiao L, Mendelsohn JB, Steplowski E, Lynch SM, Wactawski-Wende J, Arslan A, Bueno-de-Mesquita HB, Fuchs CS, Buring J, Gaziano M, Gross M, Helsouer K, Jacobs EJ, LaCroix A, Petersen G, Zheng W, Allen N, Ammundadottir L, Baofetta P, Bergman MM, Canzian F, Chanock S, Clavel-Chapelon F, Clipp S, Freiberg MS, Hankinson S, Hartge P, Hoover R, Hubbell FA, Hunter D, Jacobs K, Kraft P, Kooperberg C, Manjer J, Navarro C, Peeters PHM, Shu XO, Stevens V, Thomas G, Tjonneland A, Tobias G, Trichopoulos D, Tumino R, Vineis P, Virtamo J, Wallace R, Willett W, Wolpin B, Yu K, Seleniuch-Jacquotte A, Stolzenberg-Solomon RZ (2010). Alcohol intake and pancreatic cancer: A pooled analysis from the pancreatic cancer cohort consortium (PanScan). *Cancer Causes Control*, epub ahead of print.
148. Millen AE, Subar AF, Graubard BI, Peters U, Hayes RB, Weissfeld JL, Yokochi LA, Ziegler RG; for the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Project Team (2007). Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial. *American Journal of Clinical Nutrition*, 86 (6), 1754-1764.
149. Miller AB, Madalinska, Church T, Crawford D, Essink-Bot JL, Goel V, de Koning HJ, Maattanen L, Pentikainen T (2001). Health-related quality of life and cost-effectiveness studies in the European randomized study of screening for prostate cancer and the US Prostate, Lung, Colon, and Ovary Trial. *European Journal of Cancer*, 37, 2154-2160.
150. Miller AB, Yurgalevitch S, Weissfeld JL (2000). Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Controlled Clinical Trials*, 21 (6S), 400S-406S.
151. Mirabello L, Huang WY, Wong JYY, Chatterjee N, Reding D, Crawford ED, DeVivo I, Hayes RB, Savage SA (2009). The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. *Aging Cell*, 8 (4), 405-413.
152. Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evan DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male

Attachment 11: PLCO Manuscripts, Books & Book Chapters

- A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M, Eccles D, Axcrona K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon y Cajal T, Spigelman A, Teo SH, Nicolai N, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, Kyriacou K, van Asperen C, Kiemeny L, The IMPACT Study Collaborators, Easton DF, and Eeles RA (2011). TARGETED PROSTATE CANCER SCREENING IN MEN WITH MUTATIONS IN BRCA1 AND BRCA2 DETECTS AGGRESSIVE PROSTATE CANCER:PRELIMINARY ANALYSIS OF THE RESULTS OF THE IMPACT STUDY. *BJU Int*, 107 (1), 28-39.
153. Moore LE, Huang WY, Chatterjee N, Gunter M, Chanock S, Yeager M, Welch B, Pinsky P, Weissfeld J, Hayes RB (2005). GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced colorectal adenoma. *Cancer Epidemiol Biomarkers Prev*, 14 (7), 1823-1827.
154. Moore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, Virtamo J, Ahn J, Mayne ST, Yu H, Peters U, Gunter MJ (2009). Adipokine Genes and Prostate Cancer Risk. *Int J Cancer*, 124 (4), 869-876.
155. Morton LM, Wang SS, Bergen AW, Chatterjee N, Kvale P, Welch R, Yeager M, Hayes RB, Chanock SJ, Caporaso NE (2006). DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Pharmacogenet Genomics*, 16 (12), 901-910.
156. Mukherjee B, Chatterjee N (2007). Exploiting gene-environment independence for analysis of case-control studies: an empirical Bayes approach to trade off between bias and efficiency. *Biometrics*, Epub ahead of print.
157. Mukherjee B, Chatterjee N (2008). Exploiting gene-environment independence for analysis of case-control studies: an empirical Bayes approach to trade off between bias and efficiency. *Biometrics*, 64 (3), 685-694.
158. Mukherjee B, Liu I (2009). A note on bias due to fitting prospective multivariate generalized linear models to categorical outcomes ignoring retrospective sampling schemes. *Journal of Multivariate analysis*, 100, 459-472.
159. Mutch MG, Schoen RE, Fleshman JW, Rall CJN, Dry S, Seligson D, Charabaty A, Chia D, Umar A, Viner J, Hawk E, Pinsky PF (2009). A multicenter study of prevalence and risk factors for aberrant crypt foci. *Clinical Gastroenterology and Hepatology*, 7 (5), 568-574.
160. Nyante SJ, Black A, Kreimer AR, Duggan MA, Carreon JD, Kessel B, Buys SS, Ragard LR, Johnson KA, Dunn BK, Lamerato L, Commins JM, Berg CD, Sherman ME (2010). Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, colorectal and Ovarian (PLCO) Cancer Screening Trial. *Gynecologic Oncology*, in press.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

161. O'Brien B, Nichaman L, Browne JEH, Levin D, Prorok PC, & Gohagan JK, (2000). Coordination and management of a large multicenter screening trial: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Controlled Clinical Trials*, 21 (6S), 310S-328S.
162. Oaks BM, Dodd KW, Meinhold CL, Jiao L, Church TR, Stolzenberg-Solomon RZ (2010). Folate intake, post-folic acid grain fortification, and pancreatic cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *American Journal of Clinical Nutrition*, 91 (24), 449-455.
163. Oken MM, Marcus M, Hu P, Beck TM, Hocking W, Kvale PA, Cordes J, Riley TL, Winslow SD, Peace S, Levin DL, Prorok PC, Gohagan JK (2005). Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Journal of the National Cancer Institute*, 97 (24), 1832-1839.
164. Ortner ER, Hayes RB, Weissfeld J, Gelmann EP (2006). Effect of homeodomain protein NKX3.1 R52C polymorphism on prostate gland size. *Urology*, 67 (2), 311-315.
165. Parikh H, Deng Z, Yeager M, Boland J, Matthews C, Jia J, Collins I, White A, Burdett L, Hutchinson A, Rodesch MJ, Albert T, Halversleben HA, Harkins TT, Ahn, J, Berndt, S, OI L, Chatterjee N, Hoover R, Thomas G, Hunter D., Hayes R, Chanock SJ, Amundadottir L (2010). A comprehensive resequence analysis of the KLK15-KLK3-KLK2 loca on chromosome 19q13.33. *Human Genetics*, 127 (1), 91-99.
166. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, Andriole GL, Ogden S, Ragard LR, Buys SS (2009). Results from four rounds of ovarian cancer screening in a randomized trial. *Obstetrics and Gynecology*, 113 (4), 775-782.
167. Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorransoro M, Dossus L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PHM, Pike MC, Pollak M, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson HS (2008). IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). *PLoS One*, 3 (7), e2578.
168. Peters U, Chatterjee N, Hayes RB, Schoen RE, Chanock SJ, Foster CB. (2008). Variation in the selenoenzyme genes and risk of advanced colorectal adenoma. *Cancer Epidemiol Biomarkers Prev*, 17 (5), 1144-1154.
169. Peters U, Chatterjee N, McGlynn KA, Schoen RE, Church TR, Bresalier RS, Gaudet MM, Flood A, Schatzkin A, Hayes RB (2004). Calcium intake and colorectal adenoma in a US

Attachment 11: PLCO Manuscripts, Books & Book Chapters

- colorectal cancer early detection program. *American Journal of Clinical Nutrition*, 2004;80, 1358-65.
170. Peters U, Chatterjee N, Yeager M, Chanock SJ, Schoen RE, McGlynn KA, Church TR, Weissfeld JL, Schatzkin A, Hayes RB (2004). Association of genetic variants in the calcium-sensing receptor with risk of colorectal adenoma. *Cancer Epidemiology, Biomarkers & Prevention*, 13 (12), 2181-86.
171. Peters U, Chatterjee N, Church TR, Mayo C, Sturup S, Foster CB, Schatzkin A, Hayes RB (2006). High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program. *Cancer Epidemiology Biomarkers Prevention*, 15 (2), 315-320.
172. Peters U, Foster CB, Chatterjee N, Schatzkin A, Reding D, Andriole GL, Crawford ED, Sturup S, Chanock SJ, Hayes RB (2007). Serum selenium and risk of prostate cancer - a nested case-control study. *American Journal of Clinical Nutrition*, 85 (1), 209-217.
173. Peters U, Hayes RB, Chatterjee N, Shao W, Schoen RE, Pinsky P, Hollis BW, McGlynn KA, PLCO Project Team (2004). Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk. *Cancer Epidemiology, Biomarkers & Prevention*, 13 (4), 546-552.
174. Peters U, Leitzmann MF, Chatterjee N, Wang WY, Albanes D, Gelmann EP, Friesen MF, Riboli E, Hayes RB (2007). Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Cancer Epidemiology Biomarkers and Prevention*, 16 (5), 962-968.
175. Peters U, Sinha R, Chatterjee N, Subar A, Ziegler RG, Kulldorff M, Bresalier R, Weissfeld JL, Flood A, Schatzkin A, Hayes RB (2003). Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. *The Lancet*, 361, 1491-1495.
176. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan AA, Bueno-de-Mesquita HB, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Klein AP, LaCroix A, Li D, Mandelson MT, Olson SH, Risch HA, Zheng W, Albanes D, Bamlet WR, Berg CD, Boutron-Ruault M-C, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hankinson SE, Hassan M, Howard B, Hunter DJ, Hutchinson A, Jenab M, Kaaks R, Kooperberg C, Krogh V, Kurtz RC, Lynch SM, McWilliams RR, Mendelsohn JB, Michaud DS, Parikh H, Patel AV, Peeters PHM, Rajkovic A, Riboli E, Rodriguez L, Seminara D, Shu X-O, Thomas G, Tjonneland A, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wang Z, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Fraumeni JF, Hoover RN, Hartge P, Chanock SJ (2010). A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. *Nature Genetics*, epub ahead of print.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

177. Pinsky PF (2001). Estimation and prediction for cancer screening models using deconvolution and smoothing. *Biometrics*, 57 (2), 389-95.
178. Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK (2007). Prostate-specific antigen velocity and prostate cancer gleason grade and stage. *Cancer*.
179. Pinsky PF, Andriole GL, Kramer BS, Hayes RB, Prorok PC, Gohagan JK (2005). Prostate biopsy following a positive screen in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Journal of Urology*, 173 (March), 746-751.
180. Pinsky PF, Black A, Kramer BS, Miller A, Prorok P, Berg C (2010). Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Clinical Trials*, Epub ahead of print.
181. Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, Greenlee R, Gohagan JK (2007). Repeat prostate biopsy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *British Journal of Urology International*, 99 (4), 775-779.
182. Pinsky PF, Fleshman J, Mutch M, Rail C, Charabaty A, Seligson D, Dry S, Umar A, Schoen RE (2010). One year recurrence of aberrant crypt foci. *Cancer Prevention Research*, 3 (7), 839-843.
183. Pinsky PF, Ford M, Gamito E, Higgins D, Jenkins V, Lamerato L, Tenorio S, Marcus P, Gohagan JK. (2008). Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Journal of the National Medical Association*, 100 (3), 291-298.
184. Pinsky PF, Freedman M, Kvale P, Oken M, Caporaso N, Gohagan J (2006). Abnormalities on chest radiograph reported in subjects in a cancer screening trial. *Chest*, 30 (3), 688-693 (3), 688-693.
185. Pinsky PF, Kramer BS, Crawford ED, Grubb RL, Urban DA, Andriole GL, Chia D, Levin DL, Gohagan, JK (2006). Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. *Urology*, 68 (2), 352-356.
186. Pinsky PF, Kramer BS, Reding D, Buys S (2003). Reported family history of cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *American Journal of Epidemiology*, 157 (9), 792-9.
187. Pinsky PF, Miller A, Kramer BS, church T, Reding D, Prorok P, Gelmann E, Schoen RE, Buys S, Hayes RB, Berg CD (2007). Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Am J Epidemiol*, 165 (8), 874-881.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

188. Pinsky PF, Schoen RE, Weissfeld JL, Bresalier RS, Hayes RB, Gohagan JK (2003). Predictions of advanced proximal neoplasia in persons with abnormal screening flexible sigmoidoscopy. *Clinical Gastroenterology and Hepatology*, 1 (2), 103-110.
189. Pinsky PF, Schoen RE, Weissfeld JL, Church T, Yokochi LA, Doria-Rose VP, Prorok P (2009). The yield of surveillance colonoscopy by adenoma history and time to examination. *Clinical Gastroenterol Hepatol*, 7, 86-92.
190. Pinsky PF, Schoen RE, Weissfeld JL, Kramer B, Hayes RB, Yokochi L for the PLCO Project Team (2005). Variability in flexible sigmoidoscopy performance among examiners in a screening trial. *Clinical Gastroenterology and Hepatology*, 3, 792-797.
191. Prorok PC (1994). The National Cancer Institute multi-screening trial. *Canadian Journal of Oncology*, 4 (1), S98-101.
192. Prorok PC, Andriole GL, Bresalier R, Buys S, Chia D, Crawford ED, Fogel R, Gelman EP, Gilbert F, Hasson MA, Hayes R, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken M, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK (2000). Design of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. *Controlled Clinical Trials*, 21 (6S), 273S-309S.
193. Prorok PC, Byar DP, Smart CR, Baker SG, Connor RJ (1991). Cancer Screening. In Miller AB, Chamberlain J, Dah NE, Hakama M, Prorok PC (Ed.), *Evaluation of Screening for Prostate, Lung, Colorectal cancers: the PLC Trial*. (pp. 300-320). University Press, Cambridge, UK: Cambridge University Press for International Union Against Cancer (UICC).
194. Prorok PC, Marcus PM (2010). Cancer screening trials: Nuts and bolts. *Seminars in Oncology*, 37 (3), 216-223.
195. Prorok PC, Potosky AL, Gohagan JK, Kramer BS (1996). *Advances in Cancer Screening*. In Miller AB (Ed.), *Prostate Cancer Screening: Current Issues*. (pp. 93-112). Boston, MA: Kluwer Academic Publishers.
196. Purdue MP, Freedman DM, Gapstur SM, Helzlsouer KJ, Laden F, Lim U, Maskarinec G, Rothman N, Shu X-O, Stevens VL, Zeleniuch-Jacquotte A, Albanes D, Bertrand K, Weinstein SJ, Yu K, Irish L, Horst RL, Hoffman-Bolton J, Giovannucci EL, Kolonel LN, Snyder K, Willett W, Arslan AA, Hayes RB, Zheng W, Xiang Y-B, Hartge P (2010). Circulating 25-hydroxyvitamin D and risk of non-Hodgkin lymphoma Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. *American Journal of Epidemiology*, 172 (1), 58-69.
197. Purdue MP, Freedman DM, Gapstur SM, Helzlsouer KJ, Laden F, Lim U, Maskarinec G, Rothman N, Shu X-O, Stevens VL, Zeleniuch-Jacquotte A, Albanes D, Bertrand K, Weinstein SJ, Yu K, Irish L, Horst RL, Hoffman-Bolton J, Giovannucci EL, Kolonel LN, Snyder K, Willett W, Arslan AA, Hayes RB, Zheng W, Xiang Y-B, Hartge P (2010).

Attachment 11: PLCO Manuscripts, Books & Book Chapters

- Circulating 25-hydroxyvitamin D and risk of non-Hodgkin lymphoma Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. *American Journal of Epidemiology*, 172 (1), 58-69.
198. Purdue MP, Freedman DM, Gapstur SM, Helzsouer KJ, Laden F, Lim U, Maskarinec G, Rothman N, Shu XO, Stevens VL, Zeleniuch-Jacquotte A, Albanes D, Bertrand K, Weinstein SJ, Yu K, Irish L, Horst RL, Hoffman-Bolton J, Giovannucci EL, Kolonel LN, Snyder K, Willett W, Arslan AA, Hayes RB, Zheng W, Xiang YB, Hartge P (2010). Circulating 25-hydroxyvitamin D and risk of non-Hodgkin lymphoma Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. *American Journal of Epidemiology*, epub ahead of print.
199. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, Moore LE, Prokhortchouk E, Wu X, Kiemeny LA, Gaborieau V, Jacobs KB, Chow W-H, Zaridze D, Matveev V, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Bucur A, Bencko V, Foretova L, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL, Boeing H, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, Duell E, Quiros JR, Sanchez M-J, Navarro C, Ardanaz E, Dorronsoro M, Khaw K-T, Allen NE, Bueno-de-Mesquita HB, Peeters PHM, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjonneland A, Romieu I, Riboli E, Mukeria A, Shangina O, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Weinstein SJ, Virtamo J, Vatten L, Hveem K, Njolstad I, Tell GS, Stoltenberg C, Kumar R, Koppova K, Cussenot O, Benhamou S, Oosterwijk E, Vermeulen SH, Aben KKH, van der Marel SL, Ye Y, Wood CG, Pu X, Mazur AM, Boulygina ES, Chekanov NN, Foglio M, Lechner D, Gut I, Heath S, Blanche H, Hutchinson A, Thomas G, Wang Z, Yeager M, Fraumeni JF, Skryabin KG, McKay JD, Rothman N, Chanock SJ, Lathrop M, Brennan P. (2011). Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. *Nature Genetics*, 43 (1), 60-67.
200. Purdue MP, Lan Q, Martinez-Maza O, Oken MM, Hocking W, Huang W-Y, Baris D, Conde B, Rothman N (2009). A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. *Blood*, 114 (13), 2730-2732.
201. Purdue MP, Mink PJ, Hartge P, Huang WY, Buys S, Hayes RB (2005). Hormone replacement therapy, reproductive history, and colorectal adenomas: data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (United States). *Cancer Causes and Control*, 16, 965-973.
202. Reynolds T (1996). Screening and prevention trials step up minority recruitment. *Journal of the National Cancer Institute (JNCI)*, 88 (18), 1265-1267.
203. Ristvedt ST, McFarland EG, Weinstock LB, Thyssen EP (2003). Patient preferences for CT colonography, conventional colonoscopy, and bowel preparation. *The American Journal of Gastroenterology*, 98 (3), 578-585.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

204. Schairer C, McCarty CA, Isaacs C, Suej LY, Pollak MN, Berg CD, Ziegler RG (2010). Circulating insulin-like growth factor (IGF) –1 and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) cohort. *Hormones and Cancer*, 1 (2), 100-111.
205. Schenk JM, Riboli E, Chatterjee N, Leitzmann MF, Ahn J, Albanes D, Reding DJ, Wang Y, Friesen MD, Hayes RB, Peters U (2009). Serum retinol and prostate cancer risk: A nested case-control study in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Cancer Epidemiology Biomarkers & Prevention*, 18 (4), 1227-1231.
206. Schoen R, Weissfeld J et al (2000). Patient satisfaction with screening flexible sigmoidoscopy. *Archives of Internal Medicine*, 160 (12), 1790-1796.
207. Schoen RE, Mutch M, Rall C, Dry SM, Seligson D, Umar A, Pinsky P (2008). The natural history of aberrant crypt foci (ACF). *Gastrointestinal Endoscopy*, 67 (7), 1097-1102.
208. Schoen RE, Pinsky PF, Weissfeld JL, Bresalier RS, Church T, Prorok P, Gohagan JK (2003). Results of repeat sigmoidoscopy 3 years after a negative examination. *JAMA*, 290 (1), 41-48.
209. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Reding DJ, Hayes RB, Church, T, Yurgalevitch S, Doria-Rose VP, Hickey T, Riley T, Berg CD (2010). Utilization of surveillance colonoscopy in community practice. *Gastroenterology*, 138 (14), 73-81.
210. Schoen RE, Schragin J, Weissfeld JL, Thaete FL, Evans RW, Rosen CJ, Kuller LH (2002). Lack of association between adipose tissue distribution and IGF-1 and IGFBP-3 in men and women. *Cancer Epidemiology, Biomarkers and Prevention*, 11, 581-586.
211. Schoen RE, Weissfeld JL, Kuller LH, Thaete FL, Evans RW, Hayes RB, Rosen CJ (2005). Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. *Gastroenterology*, 129 (2), 464-475.
212. Schoen RE, Weissfeld JL, Pinsky PF, Riley T (2006). Yield of advanced adenoma and cancer based polyp size detected at screening flexible sigmoidoscopy. *Gastroenterology*, 131 (6), 1683-1689.
213. Schonfeld SJ, Pee D, Greenlee RT, Hartge P, Lacey JV, Park Y, Schatzkin A, Visvanathan K, Pfeiffer RM (2010). Effect of changing breast cancer incidence rates on the calibration of the Gail Model. *Journal of Clinical Oncology*, 28 (14), 2411-2217.
214. Schumacher FR, Feigelson S, Cox DG, Haiman CA, Albanes D, Buring J, Calle EE, Chanock SJ, Colditz GA, Diver WR, Dunning AM, Freedman ML, Gaziano JM, Giovannucci E, Hankinson SE, Hayes RE, Henderson BE, Hoover RN, Kaaks R, Key T, Kolonel LN, Kraft P, Le Marchand L, Ma J, Pike MC, Riboli E, Stampher MJ, Stram DO, Thomas G, Thun MJ, Travis R, Virtamo J, Andriole G, Gelmann E, Willett WC, Hunter DJ

Attachment 11: PLCO Manuscripts, Books & Book Chapters

- (2007). A common 8q24 variant in prostate and breast cancer from a large nested case-control study. *Cancer Research*, 67 (7), 2951-2956.
215. Seth A. Strope SA & Andriole GL (2010). Prostate cancer screening: current status and future perspectives. *Nature Reviews Urology* 7, 487-493 (September 2010) |, 7, 487-493.
216. Sherman ME, Lacey JV, Buys SS, Reding DJ, Berg CD, Williams C, Hartge P (2006). Ovarian volume: determinants and associations with cancer among postmenopausal women. *Cancer Epidemiol Biomarkers Prev*, 15 (8), 1550-1554.
217. Shteynshlyuger A, Andriole GL (2010). Prostate cancer: To screen or not to screen?. *Urol Clin J Am*, 37, 1-9.
218. Sigurdson AJ, Jones IM, Wei Q, Wu X, Spitz MR, Stram DA, Gross MD, Huang WY, Wang LE, Gu J, Thomas CB, Reding DJ, Hayes RB, Caporaso NE. (2011). Prospective analysis of DNA damage and repair markers of lung cancer risk from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Carcinogenesis*, 32 (1), 69-73.
219. Simpson NK, Johnson CC, Ogden S, Gamito E, Trocky N, McGuire C, Martin J, Barrow S, Lamerato L, Flic (2000). Recruitment strategies in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: the first six years. *Controlled Clinical Trials*, 21 (6S), 356S-378S.
220. Sinha R, Peters U, Cross AM, Kulldorff M, Weissfeld JL, Pinsky PF, Rothman N, Hayes RB, and the Prostate, Lung, Colorectal, and Ovarian Cancer Project Team (2005). Meat, meat cooking methods and preservation, and risk for colorectal adenoma. *Cancer Research*, 65 (17).
221. Sit SY, Modugno F, Hill LM, Martin J, Weissfeld JL (2004). Transvaginal ultrasound measurement of endometrial thickness as a biomarker for estrogen exposure. *Cancer Epidemiol Biomarkers Prev*, 13 (9), 1459-1465.
222. Stallings FL, Ford ME, Simpson NK, Fouad M, Jernigan JC, Trauth JM, Miller DS (2000). Black participation in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. *Controlled Clinical Trials*, 21 (6S), 379S-389S.
223. Stevens VL, Ahn J, Sun J, Jacobs EJ, Moore SC, Patel AV, Berndt SI, Albanes D, Hayes RB (2010). HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. *The Prostate*, 70 (6), 601-607.
224. Stolzenberg-Solomon RZ, Chang SC, Leitzmann MF, Johnson KA, Johnson C, Buys SS, Hoover RN, Ziegler RG (2006). Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *American Journal of Clinical Nutrition*, 83, 895-904.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

225. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel A, Helzlsouer KJ, Weinstein SJ, McCullough ML, Purdue MP, Shu X-O, Snyder K, Virtamo J, Wilkins LR, Yu K, Zeleniuch-Jacquotte A, Zheng W, Albanes D, Cai Q, Harvey C, Hayes R, Clipp S, Horst RL, Irish L, Koenig K, Le Marchand L, Kolonel LN (2010). Circulating 25-hydroxyvitamin and risk of pancreatic cancer: Cohort Consortium vitamin D Pooling Project of Rarer Cancers. *American Journal of Epidemiology*, 172 (1), 81-93.
226. Stolzenberg-Solomon RZ, Hayes RB, Horst RL, Anderson KE, Hollis BW, Silverman DT (2009). Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. *Cancer Research*, 69 (4), 1439-1447.
227. Stroe SA & Andriole GL (2010). Prostate Cancer Screening: Current status and future perspectives. *Nature Reviews Urology*, 7, 487-493.
228. Sturup, S, Hayes RB, Peters U (2005). Development and application of a simple routine method for the determination of selenium in serum by octopole reaction system ICPMS. *Anal Bioanal Chem*, 381, 686-694.
229. Subar AF, Ziegler RG, Rhompson FE, Johnson CC, Weissfeld JL, Reding D, Kavounis KH, Hayes RB (2001). Is shorter always better? relative importance of questionnaire length and cognitive ease on response rates and data quality for two dietary questionnaires. *American Journal of Epidemiology*, 153 (4).
230. Sue LY, Schairer C, Ma X, Williams C, Chang SC, Miller AB, McCarty CA, Willcox BJ, Ziegler RG (2009). Energy intake and risk of postmenopausal breast cancer: An expanded analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Cancer Epidemiology Biomarkers and Prevention*, 18 (11), 2842-2850.
231. Tammemagi CM, Freedman MT, Church, TR, Oken MM, Hocking W, Kvale PA, Hu P, Riley TL, Ragard L, Prorok PC, Berg CD (2007). Factors associated with small aggressive non-small cell lung cancer. *Cancer Epidemiology, Biomarkers & Prevention*, 16 (10), 2082-2089.
232. Tammemagi CM, Freedman MT, Pinsky PF, Oken MM, Hu P, Riley TL, Ragard LR, Berg CD, Prorok PC (2009). Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs – A Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial study. *Journal of Thoracic Oncology*, 4 (6), 710-721.
233. Tasevska N, Cross AJ, Dodd KW, Ziegler RG, Caporaso NE, Sinha R for PLCO Project Team (2010). No effect of meat, meat cooking preferences, meat mutagens or heme iron on lung cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *International Journal of Cancer*, epub ahead.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

234. Taylor KL, Cox LS, Zincke N, Mehta L, McGuire C, Gelmann E (2007). Lung cancer screening as a teachable moment for smoking cessation. *Lung Cancer*, 56 (1), 125-134.
235. Taylor KL, Shelby R, Gelmann E, McGuire C (2004). Quality of life and trial adherence among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Journal of the National Cancer Institute (JNCI)*, 96 (14), 1083-1094.
236. Taylor KL, Shelby RA, Schwartz MD, Ackerman JL, Vholland, Gelman EP, McGuire C (2002). The impact of item order on ratings of cancer risk perception. *Cancer Epidemiology, Biomarkers, & Prevention*, 11, 654-659.
237. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. (2008). Multiple loci identified in a genome-wide association study of prostate cancer.. *Nature Genetics*, 40 (3), 310-315.
238. Trauth JM, Jernigan JC, Siminoff LA, Musa D, Neal-Ferguson D, Weissfeld J (2005). Factors affecting older African American women's decisions to join the PLCO Cancer Screening Trial. *Journal of Clinical Oncology*, 23 (34), 8730-8738.
239. Travis RC, Schumacher F, Hirschhorn JN, Kraft P, Allen NE, Albanes D, Berglund G, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Calle EE, Chanock S, Dunning AM, Hayes R, Feigelson HS, Gaziano JM, Giovannucci E, Haiman CA, Henderson BE, Kaaks R, Kolonel LN, Ma J, Rodriguez L, Riboli E, Stampfer M, Stram DO, Thun MJ, Tjonneland A, Trichopoulos D, Vineis P, Virtamo J, LeMarchand L, Hunter DJ. (2009). CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. *Cancer Epidemiology, Biomarkers and Prevention*, 18 (10), 2734-2744.
240. Troy JD, Hartge P, Weissfeld JL, Oken MM, Colditz GA, Mechanic LE, Morton LM (2010). Associations between anthropometry, cigarette smoking, alcohol consumption, and non-Hodgkin lymphoma in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *American Journal of Epidemiology*, 171 (12), 1270-1281.
241. Tsai H-T, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB, Marti GE, Albitar M, Ghia P, Rajkumar SV, Landgren O (2009). Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. *Blood*, 114 (24), 4928-4932.
242. Wang J, Lin M, Crenshaw A, Hutchinson A, Hicks B, Yeager M, Berndt S, Huang WY, Hayes RB, Chanock SJ, Jones R, Ramakrishnan R (2009). High-throughput single nucleotide polymorphism genotyping using nanofluidic dynamic arrays. *BMC Genomics*, 10, 561.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

243. Wang SS, Morton LM, Bergen AW, Lan EZ, Chatterjee N, Kvale P, Hayes RB, Chanock SJ, Caporaso NE. (2007). Genetic variation in catechol-O-methyltransferase (COMT) and obesity in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.. *Human Genetics.*, 122 (1), 41-49.
244. Washko GR, Dransfield MT, Estepar RSJ et al (2008). Airway wall intensity: A novel CT metric of airway disease in COPD. *American Journal of Respiratory Critical Care Medicine*, 177, A285.
245. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Chia D, Crawford ED (2007). IGF-1 and IGFBP-3: risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *International Journal of Cancer*, 121, 2267-2273.
246. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Hsing AW, Crawford ED, Andriole GL, Kaaks R, Hayes RB. (2008). Endogenous sex hormones and the risk of prostate cancer: A prospective study.. *International Journal of Cancer*, 122, 2345-2350.
247. Weissfeld J, Fagerstrom R, O'Brien B (2000). Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. *Controlled Clinical Trials*, 21 (6S), 390S-399S.
248. Weissfeld JL, Ling BS, Schoen RE, Bresalier RS, Riley T, Prorok P (2002). Adherence to repeat screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. *Cancer*, 94, 2569-76.
249. Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Church T, Yurgalevitch S, Austin JH, Prorok PC, Gohagan JK for the PLCO Project Team (2005). Flexible sigmoidoscopy in the PLCO Cancer Screening Trial: results from the baseline screening examination of a randomized trial. *Journal of the National Cancer Institute*, 97 (13), 989-997.
250. Wendelboe AM, Hegmann KT, Alder SC, White GL, Gren LH, Lyon JL (2004). Associations between body-mass index and surgery for rotator cuff tendinitis. *The Journal of Bone and Joint Surgery*, 86-A (4), 743-747.
251. Wendelboe AM, Hegmann KT, Biggs JJ, Cox CC, Portmann AJ, Gildea JH, Gren LH, Lyon JL (2003). Relationships between body mass indices and surgical replacements of knee and hip joints. *American Journal of Preventive Medicine*, 25 (4), 290-295.
252. Whiting BR, McFarland EG, Brink JA (2000). Influence of image acquisition parameters on CT artifacts and polyp depiction in spiral CT colonography in vitro evaluation. *Radiology*, 217 (1), 165-172.
253. Willer CJ, Speliotes EK, Loos RJF, Li S, Lindgren CM, Heid IM, Berndt SI, Elliott AL, Jackson AU, Lamina C, Lettre G, Lim N, Lyon HN, McCarroll SA, Papadakis K, Qi L, Randall JC, Roccascocca RM, Sanna S, Scheet P, Weedon MN, Wheeler E, Zhao JH, Jacobs LC, Prokopenko I, Soranzo N, Tanaka T, Timpson NJ, Almgren P, Bennett A, Bergman RN,

Attachment 11: PLCO Manuscripts, Books & Book Chapters

- Bingham SA, Bonnycastle LL, Brown M, Burt NP, Chines P, Coin L, Collins FS, Connell JM, Cooper C, Smith GD, Dennison EM, Deodhar P, Elliott P, Erdos MR, Estrada K, Evans DM, Gianniny L, Gieger C, Gillson CJ, Guiducci C, Hackett R, Hadley D, Hall AS, Havulinna AS, Hebebrand J, Hofman A, Isomaa B, Jacobs KB, Johnson T, Jousilahti P, Jovanovic Z, Khaw KT, Kraft P, Kuokkanen M, Kuusisto J, Laitinen J, Lakatta EG, Luan J, Luben RN, Mangino M, McArdle WL, Meitinger T, Mulas A, Munroe PB, Narisu N, Ness AR, Northstone K, O'Rahilly S, Purmann C, Rees MG, Ridderstråle M, Ring SM, Rivadeneira F, Ruokonen A, Sandhu MS, Saramies J, Scott LJ, Scuteri A, Silander K, Sims MA, Song K, Stephens J, Stevens S, Stringham HM, Tung YC, Valle TT, Van Duijn CM, Vimalaswaran KS, Vollenweider P, Waeber G, Wallace C, Watanabe RM, Waterworth DM, Watkins N; Wellcome Trust Case Control Consortium, Witteman JC, Zeggini E, Zhai G, Zillikens MC, Altshuler D, Caulfield MJ, Chanock SJ, Farooqi IS, Ferrucci L, Guralnik JM, Hattersley AT, Hu FB, Jarvelin MR, Laakso M, Mooser V, Ong KK, Ouwehand WH, Salomaa V, Samani NJ, Spector TD, Tuomi T, Tuomilehto J, Uda M, Uitterlinden AG, Wareham NJ, Deloukas P, Frayling TM, Groop LC, Hayes RB, Hunter DJ, Mohlke KL, Peltonen L, Schlessinger D, Strachan DP, Wichmann HE, McCarthy MI, Boehnke M, Barroso I, Abecasis GR, Hirschhorn JN; Genetic Investigation of ANthropometric Traits Consortium (2009). . Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. *Nature Genetics*, 41 (1), 25-34.
254. Wolpin BM, Kraft P, Gross M, Helzlsouer K, Bas Bueno-de-Mesquita H, Steprowski E, Stolzenberg-Solomon RZ, Arslan AA, Jacobs EJ, LaCroix A, Petersen G, Zheng W, Albanes D, Allen NE, Amundadottir L, Anderson G, Boutron-Ruault M-C, Buring JE, Canzian F, Chanock SJ, Clipp S, Gaziano JM, Giovannucci EL, Hallmans G, Hankinson SE, Hoover RN, Hunter DJ, Hutchinson A, Jacobs K, Kooperberg C, Lynch SM, Mendelsohn JB, Michaud ds, Overvad K, Patel AV, Rajkovic A, Sanchéz M-J, Shu X-O, Slimani N, Thomas G, Tobias GS, Trichopoulos D, Vineis P, Virtamo J, Wactawski-Wende J, Yu K, Zeleniuch-Jacquotte A, Hartge P, and Fuchs CS (2010). Genotype-Derived ABO Blood Group Alleles and the Risk of Pancreatic Cancer: Data from the Pancreatic Cancer Cohort Consortium. *Cancer Res*, 70 (3), 1015-1023.
255. Wong HL, Peters U, Hayes RB, Huang WY, Schatzkin A, Bresalier RS, Velie EM & Brody LC. (2010). Polymorphisms in the adenomatous polyposis coli (APC) gene and advanced colorectal adenoma risk. *European Journal of Cancer*, epub ahead of print.
256. Xu J, Sun J, Kader AK, Lindstrom S, Wiklund F, Hsu FC, Johansson JE, Zheng SL, Thomas G, Hayes RB, Kraft P, Hunter DJ, Chanock SJ, Isaacs WB, Gronberg H (2009). Estimation of absolute risk for prostate cancer using genetic markers and family history. *Prostate*, 69 (14), 1565-1572.
257. Xu J, Zheng SL, Isaacs SD, Wiley KE, Wiklund F, Sun J, Kader AK, Li G, Purcell LD, Kim S-T, Hsu F-C, Stattin P, Hugosson J, Adolfsson J, Walsh PC, Trent JM, Duggan D, Carpten J, Grönberg H, and Isaacs WB (2010). Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. *Proc Natl Acad Sci U S A*, 107 (5), 2136-2140.

Attachment 11: PLCO Manuscripts, Books & Book Chapters

258. Yeager M, Deng Z, Boland J, Matthews C, Baciorek J, Lonsberry V, Hutchinson A, Burdett LA, Qi L, Jacobs KB, Gonzalez-Bosquet J, Berndt S, Hayes R, Hoover R, Thomas G, Hunter DJ, Dean M, Chanock SJ (2009). Comprehensive resequence analysis of a 97 kb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer. *Human Genetics*, 126 (6), 743-750.
259. Yeager N, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF, Hoover R, Hunter DJ, Chanock SJ, Thomas G (2007). Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. *Nature Genetics*, 39, 645-649.
260. Yu YY, Pinsky PF, Caporaso NE, Chatterjee N, Baumgarten M, Langenberg P, Furuno J, Lan Q, Engels EA (2008). Lung cancer risk following detection of pulmonary scarring on chest radiography in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Archives of Internal Medicine*, 168 (21), 2326-2332.
261. Zeleniuch-Jacquotte A, Gallicchio L, Hartmuller V, Helzlsouer KJ, McCullough ML, Setiawan VW, Shu X-O, Weinstein SJ, Weiss JM, Arslan AA, De Vito I, Gao Y-T, Hayes RB, Henderson BE, Horst R, Koenig KL, Patel AV, Purdue MP, Snyder K, Steplowski E, Weinstein SJ, Yu K, Zheng W, Hankinson (2010). Circulating 25-hydroxyvitamin D and risk of endometrial cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. *American Journal of Epidemiology*, 172 (1), 36-46.
262. Zheng SL, Stevens VL, Wiklund F, Isaacs SD, Sun J, Smith S, Pruett K, Wiley KE, Kim S-T, Zhu Y, Zhang Z, Hsu F-C, Turner AR, Johansson J-E, Liu W, Kim JW, Chang B-L, Duggan D, Carpten J, Rodriguez C, Isaacs W, Grönberg H, and Xu J (2009). Two independent prostate cancer risk associated loci at 11q13. *Cancer Epidemiol Biomarkers Prev*, 18 (6), 1815-1820.
263. Zheng W, Danforth KN, Tworoger SS, Goodman MT, Arslan AA, Patel AV, McCullough ML, Weinstein SJ, Kolonel LN, Purdue MP, Shu X-O, Snyder K, Steplowski E, Visvanathan K, Yu K, Zeleniuch-Jacquotte A, Gao Y-T, Hankinson SE, Harvey C, Hayes RB, Henderson BE, Horst RL, Helzlsouer KJ (2010). Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rare Cancers. *American Journal of Epidemiology*, 172 (1), 70-80.